The R2 Team


R2 Innovations, LLC was founded by Robert L. Senter and Robert E. Matuszewski in 1998, a privately owned, Colorado based, Limited Liability Company. Sievers Biotech joined the company in 2016 adding new technologies to transition R2’s cannabidiol and cannabis oils into an extremely fine dry powder for deep lung inhalation supported by US Patent Application, 20160228385. The combined talents of Sievers Biotech with the support of its analytical chemist, engineers and advanced technologies allows development and testing of the 1st CBD / cannibals powdered metered dose inhaler directed at the treatment of asthma, a common chronic inflammatory disease of the airways and other pulmonary diseases


R2’s MISSION is to be recognized as a worldwide leader in natural remedies and prescription cannabidiol pharmaceutical medicines directed at specific ailments supported by independent clinical studies and protected by US patents.


R2's VISION is to lead the global marketplace in advanced alternative medications with emphasis on respiratory therapies, supported by; clinical research, double blind studies, duplicated independent lab testing and supported by R2’s proprietary cannabidiol medicines/formulations utilizing chosen delivery systems that eliminate the adverse side effects of current synthetic medications.


co-Founder & Managing Partner

An industry leading medical and surgical specialist since 1980 with a focus on intellectual property and product development for various medical and high-tech industries, including anti-static, anti-microbial, EMI products for the medical, textile, military, aerospace industries and polymer and polymer/ lenticular products for the sports industry. 

Mr. Senter has focused his efforts on cannabidiol and cannabis derived formulations directed at alternative medicines and formulations for the treatment of pulmonary diseases.


15-years experience in research & development of various, Medical, High-Tech, Mobile and Consumer products. Specialist in product development and systems integration with a focus on driving strategies that result in revenue growth in targeted verticals within a given industry and integrating analytical insights. 

Robert has brought a multitude of innovative products to market domestically and abroad through systems, proven steps, procedures and a sense of urgency approach towards production, manufacturing and attention to detail. 


Department of Medicine, UCLA School of Medicine, Los Angeles, Ca

Dr. Tashkin is an American pulmonologist and professor of medicine at the University of California, Los Angeles, who has studied the respiratory effects of cannabis and
related research to the effects of marijuana on the pulmonary system for 30+ years.
Dr. Tashkin was most recently in charge of a large case-control study on marijuana and the risk of cancer. Contrary to his group's expectations, the study found no increase in lung cancer risk even among heavy users of marijuana. Dr. Tashkins involvement and affiliations include: Medical Director, Pulmonary Function Laboratory, David Geffen School of Medicine, University of California, Los Angeles (UCLA) Professor of Medicine, David Geffen School of Medicine, UCLA Physician, Pulmonary and Critical Care Medicine, UCLA Medical Center Co-Director, Asthma and Cough Center, UCLA Exercise Physiology Laboratory Physician, Heartburn Treatment Center and UCLA Heartburn Treatment Center.

Christopher O. Hoyte MD
University of Colorado Hospital (UCH) - Medical Toxicologist at Rocky Mountain Poison Drug Center (RMPDC) and Director, Medical Toxicology Clinic, University of Colorado Anschutz Medical Campus 

RMPDC has been one of the nation’s premier poison centers for over 50 years. We’ve done more than successfully manage poison exposures and public health incidents both in Colorado and nationally. We’ve done more than hire the best poison information providers and healthcare specialists in America. And we’ve done more than save lives worldwide, including the life of a US President. Our guidelines are nationally-recognized and formed the foundation of Poisindex ®, the international information system that all poison centers use.

Flavia Hoyte, MD
Director, Allergy and Clinical Immunology Fellowship
Department of Medicine
Division of Allergy and Clinical Immunology

Areas of practice and expertise: 
  • Allergy
  • Asthma
Dr.  Hoyte is an allergy / asthma expert and assistant professor of medicine at National Jewish Health. Her research interests include asthma, allergic rhinitis and immunology with several projects that relate to questions raised in her clinical practice.
Flavia is board certified by the American Board of Internal Medicine and the American Board of Pediatrics. 

Dr. Hoyte received her MD from New York University School of Medicine and completed a residency at The University of Chicago Hospitals and a fellowship at National Jewish Health

Share by: